Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Brief Summary: This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.


Options:
A: Arm Label: Arm I (temozolomide, irinotecan hydrochloride, temsirolimus); Type: EXPERIMENTAL; Interventions: Drug: Irinotecan Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Temozolomide, Drug: Temsirolimus | Arm Label: Arm II (temozolomide, irinotecan hydrochloride, dinutuximab); Type: EXPERIMENTAL; Interventions: Biological: Dinutuximab, Drug: Irinotecan Hydrochloride, Other: Laboratory Biomarker Analysis, Biological: Sargramostim, Drug: Temozolomide | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Irinotecan Hydrochloride; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus), Arm II (temozolomide, irinotecan hydrochloride, dinutuximab) | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)
B: Arm Label: Arm I (isotretinoin) (closed to accrual as of 4/16/2009); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: Dinutuximab, Drug: Isotretinoin, Other: Laboratory Biomarker Analysis, Other: Pharmacological Study, Other: Quality-of-Life Assessment, Biological: Sargramostim | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Dinutuximab; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: DRUG; Name: Isotretinoin; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (isotretinoin) (closed to accrual as of 4/16/2009), Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm II (sargramostim, dinutuximab, aldesleukin, isotretinoin)
C: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Anti-GD2 antibody | Intervention Type: BIOLOGICAL; Name: Anti-GD2 antibody; Assigned to Arm(s): Group 1
D: Arm Label: R0: COJEC plus G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: G-CSF | Arm Label: R0: COJEC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R1: BuMel MAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Busulfan, Drug: Melphalan | Arm Label: R1: CEM MAT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Etoposide, Drug: Melphalan | Arm Label: R2: ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R2: ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Arm Label: R3: COJEC Induction; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vincristine, Drug: Carboplatin, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide | Arm Label: R3: Modified N7; Type: EXPERIMENTAL; Interventions: Drug: Vincristine, Drug: Etoposide, Drug: Cisplatin, Drug: Cyclophosphamide, Drug: Doxorubicin | Arm Label: R4: cnt inf ch14.18/CHO; Type: ACTIVE_COMPARATOR; Interventions: Drug: ch14.18/CHO | Arm Label: R4: cnt inf ch14.18/CHO plus Aldesleukin; Type: EXPERIMENTAL; Interventions: Drug: Aldesleukin, Drug: ch14.18/CHO | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): R0: COJEC, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: ch14.18/CHO; Assigned to Arm(s): R2: ch14.18/CHO, R2: ch14.18/CHO plus Aldesleukin, R4: cnt inf ch14.18/CHO, R4: cnt inf ch14.18/CHO plus Aldesleukin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R1: CEM MAT, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): R0: COJEC, R0: COJEC plus G-CSF, R3: COJEC Induction, R3: Modified N7 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): R3: Modified N7 | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): R0: COJEC plus G-CSF | Intervention Type: DRUG; Name: Busulfan; Assigned to Arm(s): R1: BuMel MAT | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): R1: BuMel MAT, R1: CEM MAT

Answer: B